Ohio State Navbar

Frontiers' Highlight - John C. Byrd, MD


AUSPICIOUS AGENT:  Experimental Drug Ibrutinib Highly Active in CLL Patients

Updated results from a phase Ib/II clinical trial indicate that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

Click Here to Read More

 

Study co-leader John C. Byrd, MD, who directs the Division of Hematology at Ohio State and is a member of the OSUCCC – James, presented the findings in December 2012 at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, Ga.